It plays a role in Burkitt lymphoma and prostate cancer prevention by targeting c-myc, a transcription factor of EZH2 [115, 117], and is involved in nasopharyngeal carcinoma inhibition by mitigating cyclin D3, E2, CDK4, and CDK6 along with overexpression of the CDK inhibitors p14ARF and p21CIP1 [118]. Here, EZH2 is linked to prostate carcinoma.